IL13R alpha 2 CAR-T by TCR Cure Biopharma Technology for Glioma: Likelihood of Approval

IL13R alpha 2 CAR-T is under clinical development by TCR Cure Biopharma Technology and currently in Phase I for Glioma.

Sandoz disavows U.K. trade group over dispute about promoting a biosimilar for multiple sclerosis

In an unusual move, Sandoz is no longer cooperating with a U.K. industry trade group following a dispute over allegations that the company inappropriately marketed

May 13, 2024

New hope for GI cancers: Review analyzes molecular targets and treatment advancements

Gastrointestinal (GI) cancers, encompassing esophageal, gastric, small bowel, and colorectal carcinomas, represent a significant global health burden due to their high incidence and mortality rates.

June 18, 2024

Landmark study confirms five key Parkinson’s Disease variants in largest meta-analysis

Rare Parkinson’s disease (PD) variants in a large-scale cohort.

January 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.